Electroacupuncture to treat painful diabetic neuropathy: study protocol for a three-armed, randomized, controlled pilot trial by Seunghoon Lee et al.
TRIALS
Lee et al. Trials 2013, 14:225
http://www.trialsjournal.com/content/14/1/225STUDY PROTOCOL Open AccessElectroacupuncture to treat painful diabetic
neuropathy: study protocol for a three-armed,
randomized, controlled pilot trial
Seunghoon Lee1,2, Joo-Hee Kim1,2, Kyung-Min Shin1, Jung-Eun Kim1, Tae-Hun Kim3, Kyung-Won Kang1,
Minhee Lee1, So-Young Jung1, Mi-Suk Shin1, Ae-Ran Kim1, Hyo-Ju Park1, Kwon-Eui Hong4 and Sun-Mi Choi1*Abstract
Background: The purpose of this study is to conduct a basic analysis of the effectiveness and safety of
electroacupuncture in the treatment of painful diabetic neuropathy (PDN) as compared to placebo and usual care
and to evaluate the feasibility of large-scale clinical research.
Methods/design: This study is a protocol for a three-armed, randomized, patient-assessor-blinded (to the type of
treatment), controlled pilot trial. Forty-five participants with a ≥ six month history of PDN and a mean weekly pain
score of ≥ 4 on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) will be assigned to the
electroacupuncture group (n = 15), sham group (n = 15) or usual care group (n = 15). The participants assigned to
the electroacupuncture group will receive electroacupuncture (remaining for 30 minutes with a mixed current of 2
Hz/120 Hz and 80% of the bearable intensity) at 12 standard acupuncture points (bilateral ST36, GB39, SP9, SP6, LR3
and GB41) twice per week for eight weeks (a total of 16 sessions) as well as the usual care. The participants in the
sham group will receive sham electroacupuncture (no electrical current will be passed to the needle, but the light
will be seen, and the sound of the pulse generator will be heard by the participants) at non-acupuncture points as
well as the usual care. The participants in the usual care group will not receive electroacupuncture treatment
during the study period and will receive only the usual care. The follow-up will be in the 5th, 9th and 17th weeks
after random allocation. The PI-NRS score assessed at the ninth week will be the primary outcome measurement
used in this study. The Short-Form McGill Pain Questionnaire (SF-MPQ), a sleep disturbance score (11-point Likert
scale), the Short-Form 36v2 Health Survey (SF-36), the Beck Depression Inventory (BDI) and the Patient Global
Impression of Change (PGIC) will be used as outcome variables to evaluate the effectiveness of the acupuncture.
Safety will be assessed at every visit.
Discussion: The result of this trial will provide a basis for the effectiveness and safety of electroacupuncture
for PDN.
Trial registration: Clinical Research information Service. Unique identifier: KCT0000466.
Keywords: Electroacupuncture, Painful diabetic neuropathy, Protocol* Correspondence: smchoi@kiom.re.kr
1Acupuncture, Moxibustion & Meridian Research Group, Korea Institute of
Oriental Medicine, Daejeon, Korea
Full list of author information is available at the end of the article
© 2013 Lee et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Lee et al. Trials 2013, 14:225 Page 2 of 11
http://www.trialsjournal.com/content/14/1/225Background
Diabetic peripheral neuropathy (DPN) is the most com-
mon complication of diabetes mellitus (DM), affecting
up to 50% of patients with types 1 and 2 DM [1,2]. It is
reported that approximately 16% of patients with DM
suffer from painful diabetic neuropathy (PDN) [3-5], and
its prevalence increases as life expectancies increase [6].
The symptoms of PDN are predominantly paresthesia
(sensation of numbness, prickling, tingling or burning),
dysesthesia (unpleasant or abnormal sense of touch) and
hyperesthesia (abnormal, increased sensitivity to normal
stimuli) [7]. It is often accompanied by depression, an-
xiety and sleep disturbance, adversely affecting the cap-
acity for work, health-related quality of life (HRQoL),
morbidity and society costs [3].
The etiology of diabetic neuropathy is poorly un-
derstood. However, downstream metabolic cascades in-
duced by lasting hyperglycemia have been proposed to
cause peripheral nerve injury. Underlying mechanisms
include an increased flux through the polyol pathway,
glycation and advanced glycation end-products, oxi-
dative stress, activation of protein kinase C and pro-
inflammatory processes [8]. It is known that damage to
small unmyelinated C-fibers is initiated in the early
stages of diabetes [9] and that hyperactivity of these fi-
bers results in diabetic neuropathic pain [10]. Therefore,
early detection of this impairment is suggested to pre-
vent exacerbation of neurological complications and re-
duce severe pain symptoms [11].
For this reason, intensive glycemic control care from
the early stages of DM, including insulin treatment as
initial pharmacotherapy [12] and lifestyle interventions
[13], have been recommended to prevent microvascular
complications. Moreover, intensive glycemic control has
been shown to delay the onset or slow progression of
the early stages of PDN in types 1 and 2 DM [14,15],
and maintenance hemoglobin A1c (HbA1c) levels of ap-
proximately > 6.5 to 7% are recommended in light of the
patient’s characteristics (for example, ethnicity, race or
disease duration) [16,17]. But normal maintenance of
the glycemic level is a difficult goal, and if symptoms of
PDN have occurred, it is difficult to improve them
through glycemic control. There are two agents for
symptomatic therapy, pregabalin (antiepileptics) and du-
loxetine (selective serotonin/noradrenaline reuptake in-
hibitor, SNRI), that are approved by the Food and Drug
Administration (FDA) in the USA for the treatment of
PDN. Tricyclic antidepressants, antidepressants, opioids
and topical agents have also been used to treat the pain-
ful symptoms of PDN [3,18]. Although some types of
pain medications have been known to be effective for
pain reduction, many patients with PDN are unable
to achieve a level of pain relief that is greater than
30% to 50% [18], and the long-term use of theseconventional medications may lead to significant side
effects [19,20].
Acupuncture has long been used in East Asia for pain
relief based on the Qi theory, and acupuncture can re-
duce pain by regulating the imbalance of Qi. In the
West, acupuncture has increasingly been a recent sub-
ject of research in the treatment of chronic pain. Acu-
puncture analgesia might be explained by the following
scientific mechanisms: local effect, mediated by adeno-
sine A1 receptors [21]; segmental analgesia, based on
the pain gate control theory [22]; extra-segmental anal-
gesia, the releasing of opioid peptides or descending in-
hibitory pain control [22,23] and central regulation of
the limbic system, which is relevant to the affective com-
ponent of pain [22]. In a recent, well-designed meta-
analysis of randomized clinical trials (RCTs) with data
from 17,922 patients, it was reported that acupuncture is
more effective for treating chronic pain than is sham
acupuncture and no treatment [24]. With more exten-
sive basic and clinical evidence, acupuncture is being
more widely used for various types of pain control, in-
cluding the pain of neuropathy.
According to a recent review [25] assessing the quality
of the RCTs of acupuncture in DPN, 75 RCTs that used
acupuncture as an intervention were identified for ana-
lysis through a systematic search. However, the quality
of almost all of the studies was low because the re-
searchers did not follow standard reporting guidelines,
such as the Consolidated Standards for Reporting of Tri-
als statement 2010 (CONSORT2010) and Standards for
Reporting Interventions Controlled Trials of Acupunc-
ture 2010 (STRICTA2010). No study described the me-
chanism of allocation concealment, applied the methods
of blinding or presented detailed follow-up information,
such as the study dropout rate.
Although using acupuncture for PDN is becoming
more common in clinical practice, there is no evidence
for the effectiveness and safety of the treatment that is
supported by well-designed RCTs [3]. Our study will
conduct a clinical trial with a low risk of bias to assess
the effectiveness and safety of electroacupuncture for




The aims of this study are (1) to assess the effectiveness
and safety of electroacupuncture in treating PDN for
pain, sleep disturbance, depression, HRQoL and adverse
events as compared to the usual care, (2) to evaluate the
specific effect of electroacupuncture for treating PDN as
compared to sham electroacupuncture, (3) to evaluate
the non-specific effect of electroacupuncture for treating
PDN by comparing it to sham electroacupuncture and
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large-scale clinical trial.Design and setting
This study is a stratified (whether or not a subject is ta-
king pain control medication for PDN, with equal ran-
domization), patient-assessor-blinded (to the type of
treatment), controlled, three-armed parallel-group pilot
study conducted in Korea.Recruitment period
The participants will be recruited from the Daejeon
University Hospital in Daejeon, which has a population of
approximately 1,525,000. Recruitment is expected to be
completed from June 2012 to July 2013.Methods of recruitment
A total of 45 participants with PDN will be recruited
from the outpatients of the acupuncture and moxi-
bustion clinics of Daejeon University Hospital. We will
recruit the participants by advertising in the hospital,
media (local newspapers and public newsletters) and the
Internet homepages of hospitals and public institutions.
Public lectures on DM and PDN will be conducted in
social work centers to provide information on the im-
portance of treating PDN. Because PDN patients are
rarely aware of their disease despite taking glucose con-
trol medication, we will provide information about the
trial to the doctors in the public health centers and pri-
mary care facilities in which patients are treated for glu-
cose control.Evaluation at 9th w
(primary endpoint
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Figure 1 A flowchart of the study process.Study plan
Subject information will be collected after oral and
written consent is obtained from each participant at
the first visit. This study will be conducted in three
phases (Figure 1):
1) Screening phase (one week): after a participant
consents voluntarily to the study, they will be
screened using the inclusion/exclusion criteria at the
first visit. The participants will be asked to record a
daily score in a pain diary for one week. At the end
of the screening phase, if an eligible participant
meets the study criteria with poorly controlled
neuropathic pain (moderate to severe, consistent
with stages 2 and 3 of polyneuropathy [26]), then
the subject will be randomly allocated into one of
three groups (electroacupuncture, sham or usual
care group) with a 1:1:1 allocation ratio, and will
receive eight weeks of treatment with eight weeks
of follow-up.
2) Treatment phase (eight weeks): the
electroacupuncture group will receive
electroacupuncture treatment plus the usual care,
the sham group will receive sham
electroacupuncture (minimal acupuncture
stimulation with no current at non-acupuncture
points) plus the usual care and the usual care
group will receive the usual care (an educational
program and conventional medication). Two
treatment sessions per week will be performed
during an eight-week period for 16 sessions, and
if the participants do not receive two treatments
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must be completed within four weeks. During the
treatment phase, the participants in all groups
will be permitted to take antihyperglycemic
medications (oral hypoglycemic agents or insulin
injection) with no changes in the type of
medication and minimal changes in the
maintenance dose (≤ 25%). If the participants
are taking pain control medication for PDN, that
will be permitted with no change in the
maintenance dose.
3) Post-treatment phase (eight weeks): the
participants will be assessed after eight weeks
of randomization as a primary endpoint, and the
follow-up assessment will be conducted eight
weeks after the primary endpoint. During the
post-treatment phase, pain control medication
will be allowed without limitation, but
participants will be educated to record the
usage of medication, and the records will be
checked at the follow-up assessment. To
motivate the participants to complete the study,
we will offer manual acupuncture for PDN to
the usual care group if they want to receive




Participants who meet the following conditions will be
included:
1. Males and females aged 18 to 75 years;
2. A diagnosis of type 1 or 2 DM;
3. Distal symmetric lower limb pain present for at least
six months;
4. A score ≥ 4 on the 11-point Pain Intensity
Numerical Rating Scale (PI-NRS) for the pain of
diabetic peripheral neuropathy at least four days a
week before the randomization;
5. A minimum of three scores on the history and
physical examination portion of the Korean version
of the Michigan Neuropathy Screening Instrument
(MNSI) [27];
6. A minimum of two abnormalities on the following
measures:
a. vibration perception by a 128 Hz tuning fork;
b. 10 g monofilament test;
c. ankle reflexes;
7. Stable use (variation of a major drug ≤ 25%) of
pain control medications for PDN in the three
months prior to screening or no use of pain
control medications for PDN within the past
one month.Exclusion criteria
Participants who experience or have one or more of the
following conditions will be excluded:
1. Substance abuse or dependence;
2. Cardiovascular disorder (for example, arrhythmia) or
a pacemaker;
3. Neuropsychiatric conditions (for example, epilepsy,
depression or panic disorder);
4. Other diabetic microvascular complications
(for example, diabetic nephropathy or diabetic
retinopathy) within the past three months;
5. HbA1c > 11%;
6. A change in antihyperglycemic medications in the
three months prior to screening;
7. A diagnosis of diabetic foot ulcer;
8. The presence of severe pain other than that induced
by PDN (for example, arthritis, back pain or
headache);
9. Abnormal blood test (HbA1c, blood urea nitrogen,
creatinine, thyroid-stimulating hormone,
triiodothyronine, free thyroxine, Vitamin B12) or
urine test (proteinuria);
10. Neuropathic pain caused by a condition other than
DM (for example, malignant disease, tarsal tunnel
syndrome, neurothlipsis, vitamin B12 deficiency,
hypothyroidism, neurotoxicity (for example, lead,
alcohol or smoking), medication (for example,
chemotherapy or isoniazid), transient ischemic
attack, stroke, multiple sclerosis, chronic
inflammatory demyelinating polyneuropathy, uremic
neuropathy, sub-acute combined spinal cord
degeneration, phantom limb pain or atherosclerosis
obliterans);
11. Known hypersensitivity reaction after acupuncture
treatment or an inability to cooperate with the
acupuncture procedure;
12. Electrical therapy or patch treatment (for example,
lidocaine or capsaicin) for PDN used within the past
two weeks;
13. Acupuncture, moxibustion, cupping or herbal
medicine for PDN used within the past two weeks;
14. Participation in other clinical trials within the past
three months;
15. Pregnancy, planning a pregnancy or breast-feeding;
16. Unwillingness to comply with this study protocol.
Randomization and allocation concealment
Random numbers will be generated using a compute-
rized random number generator through the stratified
block randomization method of the SAS package (Version
9.1.3; SAS institute Inc., Cary, NC, USA) with a random
block size of three prepared by a statistician (KWK) who
is blinded to this trial. A stratified random number will be
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pain control medication for PDN. Sequentially numbered,
opaque, sealed assignment envelopes will be used to en-
sure that our allocation is concealed. Each envelope will
contain a paper with the name of the group for allocation.
Random allocation will be conducted at the second visit
for participants who provide informed consent and meet
the criteria for inclusion. The two types of treatment,
electroacupuncture or sham electroacupuncture, will be
explained to the participants as ‘classical electroacu-
puncture, typically used in Korean medical clinics’ or
‘non-classical electroacupuncture, rarely used in Korean
medicine clinics’ [28]. The researcher will open the enve-
lope in front of a participant after determining that the
participant meets the criteria for inclusion and that the
enrolled participant has completed the baseline assess-
ments. Before identifying the allocation information, the
researcher will write the name of the participant and the
date on the envelope and the enclosed paper to prevent
them from being re-used. The envelopes will be kept in a
double-locked cabinet that is managed by a person not in-
volved in the study. To blind other researchers in the
study, the allocation information of the two types of acu-
puncture treatment will be recorded on a practice guide
note and be shared only with the acupuncturists.Blinding
The participants and the outcome assessors will be
blinded to the type of acupuncture, and the data man-
agers, statisticians and study monitors will be blinded to
the allocation. The sessions will be organized, if possible,
so that the participants from the different groups will
not meet. The acupuncturists will not provide any clues
about the allocation information to the participants to
blind them during the treatment and will not write this
information in a patient chart so as to blind the outcome
assessors, study monitors and data managers. The re-
searchers will treat the participants without discrimination
and will provide information about critical questions
according to the pre-scheduled standard operating proce-
dures (SOPs). The blinding will be maintained until the
study is completed, at which point all of the data will be
collected, all of the queries will be resolved and the data-
base will be locked. For the evaluation of the blinding, the
participants will be asked to assess the blinding test after
the last treatment.Intervention
The electroacupuncture treatment will be conducted by
four doctors of Korean medicine (DKMs; SL, JHK, THK
and KMS) with more than six years of college education
in Korean medicine and at least six years of clinical ex-
perience. These doctors are specialists in acupunctureand moxibustion or internists certified by the Korean
Ministry of Health and Welfare.
To maintain the same conditions, except for the need-
ling components [29], among the three groups, all of the
treatment regimens and procedures will be written in de-
tail as the pre-specified protocol and SOPs. Each practi-
tioner will be allowed to maintain a moderate interaction
with the participants: at each visit, the practitioner will ask
the participant about their recent symptoms and improve-
ment before starting the treatment and will record the an-
swers in the patient chart; the practitioner will not pursue
an excessive physical examination during the pulse-taking
or touching the subject's foot and leg and the participant
will be allowed to ask about the treatment itself without
restriction, but the practitioner will not give confident or
positive encouragement to questions about a prognosis.
This information will be shared with the practitioners in
several workshops to standardize the treatment before the
beginning of the study. With the electroacupuncture
group and the sham group, two sessions per week will be
conducted over eight weeks for a total of 16 sessions. The
treatments will be performed with disposable stainless
steel needles (0.25 × 40 mm, Dongbang Acupuncture Inc.,
Chungnam, Republic of Korea) after the acupuncture
points are sterilized with a disposable 70% isopropyl al-
cohol swab. During the treatment, the participant will
lie supine with a cushion under the knees to ensure a
stable position.
Electroacupuncture treatment
A total of 12 acupuncture points at the bilateral ST36,
GB39, SP9, SP6, LR3 and GB41 have been selected by
the consensus of professors and researchers with an acu-
puncture and moxibustion specialist license in Korea.
The selections are based on a text book [30] and litera-
ture reviews [20,31-33], and the selection of a maximum
of three individual acupuncture points (among the bilat-
eral ST44, SP2, SP3, BL66, KI1, GB43 or LR2) will be
allowed at the discretion of the practitioners. The practi-
tioner will insert the needles in the acupuncture points
and induce a deqi sensation. A battery-operated elec-
troacupuncture device (PG-306 pulse generator, Suzuki
Iryoki, Tokyo, Japan) will be connected to the handles of
each needle, which will remain in place for 30 minutes
with a mix of 2 Hz/120 Hz (altering every 2 seconds), at
5 to 10 mA and approximately 80% bearable intensity.
The practitioner will regulate the intensity by the de-
gree of the twitching of muscles, or by a request from
the subject, and can make one adjustment during the
treatment.
Sham electroacupuncture treatment
Superficial needling (3 to 5 mm) is performed without
a deqi sensation, creating a false movement that is
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ture points that are matched to each of the real acu-
puncture points.
1. Medial 1: Point 2 cm below and 2 cm medial from
SP9 with 5 mm needling;
2. Medial 2: Point 1.5 cm above and 1.5 cm medial
from SP6 with 4 mm needling;
3. Lateral 1: Point 1.5 cm below and 1.5 cm lateral
from ST36 with 5 mm needling;
4. Lateral 2: Point 1.5 cm above and 1.5 cm lateral
from GB39 with 4 mm needling;
5. Foot 1: Point 1 cm below and 0.2 cm lateral from
LR3 with 3 mm needling;
6. Foot 2: Point 1 cm below and 0.2 cm lateral from
GB41 with 3 mm needling.
The acupuncture needle is connected to the electro-
acupuncture device, but no electrical current is passed
to the needle which remains in place for 30 minutes.
The light is seen and the sound of the pulse generator is
heard by the participant as in the electroacupuncture
group.Usual care
The usual care group activities include education, coun-
seling and medications for the glucose level and pain
control. The participants will receive the educational
materials with an explanation of DM and PDN in ad-
dition to advice from the DKMs at the second visit. If
the participants use oral medication or insulin injection
for regulating their glucose levels, then they will be
allowed to continue with that medication on the con-
dition of minimal change (≤ ± 25%). If the participants
take pain control medications (for example, antiepilep-
tics, SNRIs, tricyclic antidepressants, antidepressants or
opioids), then they will be allowed to continue the medi-
cation on the condition that no change will be made
during the treatment phase. The electroacupuncture and
sham groups will also receive the care provided to the
usual care group.Co-interventions
Except for the above-stated medications, the participants
in all of the groups will not be allowed to use pain con-
trol treatments for PDN, such as electrical spinal cord
stimulation, transcutaneous electrical nerve stimulation
(TENS), laser therapy, patch therapy, herbal medicine,
psychotherapy or other acupuncture treatment. The
participants will be allowed to take a maximum of 3 g
rescue medication (acetaminophen) per day, and this
medication will be recorded in a diary.Outcome
The detailed outcome measurement time points are pro-
vided in Table 1.
Primary outcome measurement
The primary outcome with respect to the effectiveness
for PDN will be the mean change in the PI-NRS (0 = no
pain and 10 = worst possible pain, 11-point Likert scale)
from baseline to nine weeks. The PI-NRS has been
widely used to assess chronic pain intensity in conditions
like diabetic neuropathy, postherpetic neuralgia, chro-
nic low back pain, fibromyalgia and osteoarthritis in
placebo-controlled clinical trials. Compared with global
assessments of change in pain perception, the estimated
difference that is of clinical importance is a decrease of
approximately two points or approximately 30%, regard-
less of disease, gender, age, study result or treatment
group [34]. From the screening phase, the participants
will receive a daily diary to record their average pain-
related symptoms on the PI-NRS day (07:00 to 19:00)
and night (19:00 to 7:00). The participants will be ins-
tructed not to take a rescue medicine before assessing
the pain and to bring the diary to the hospital at every
visit. If a participant forgets to bring the dairy, then the
researchers will call before the next visit to identify
whether the participant is recording the diary properly
and to request compliance with presenting the diary at
each visit. We will assess the participants at the second
visit before starting the treatment and at the 5th, 9th
and 17th weeks from baseline using the PI-NRS. The
mean data during the week prior to these endpoints will
be used for the analysis.
Secondary outcome measurements
The secondary outcomes include the mean changes in
the Short-Form McGill Pain Questionnaire (SF-MPQ),
the sleep disturbance score (11-point Likert scale), the
Short-Form 36v2 Health Survey (SF-36), the Beck De-
pression Inventory (BDI) and the Patient Global Impres-
sion of Change (PGIC) at the 5th, 9th and 17th weeks
from baseline.
The SF-MPQ, developed by R. Melzack in 1987, is
a shortened scale of the MPQ. It consists of a 15-
descriptors multidimensional questionnaire, the Present
Pain Intensity (PPI) index of the standard MPQ and a
visual analogue scale (VAS). Fifteen descriptors (11 do-
mains of sensory and four domains of affective descrip-
tors) are ranked on an intensity scale as a four point
Likert scale (0 = none, 1 = mild, 2 = moderate or 3 = se-
vere) [35]. The SF-MPQ is more effective in a situation in
which the standard MPQ requires excessive time for re-
cording. Various trials for evaluating diabetic neuropathy
have used the SF-MPQ to assess the status of pain [36,37].
Kim et al. developed a Korean version of the SF-MPQ and
Table 1 Schedule for treatment and outcome measurements
Period S T P
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19






Vital signs ● ● ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ● ●
Medical history ● ● ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ● ●
Treatment expectancy questionnaire ●
Blinding test ○
Random allocation ●
Treatment ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
PI-NRS ● ● ● ● ●
SF-MPQ ● ● ● ●
Sleep disturbance score ● ● ● ●
SF-36 ● ● ● ●
Beck Depression Inventory ● ● ● ●
PGIC ● ● ● ●
Safety assessment ● ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ ○ ○ ○ ○ ● ●
P post-treatment phase, PGIC Patient Global Impression of Change, PI-NRS 11-point Pain Intensity Numerical Rating Scale, S screening phase, SF-36 Short-Form
36v2 Health Survey, SF-MPQ Short-Form McGill Pain Questionnaire, T treatment phase, ● All groups, ○ Both the electroacupuncture and sham group.
Lee et al. Trials 2013, 14:225 Page 7 of 11
http://www.trialsjournal.com/content/14/1/225assessed its reliability and validity for use with Korean
patients [38].
The sleep disturbance score will be recorded in a daily
diary on an 11-point Likert scale (0 = no interference
with sleep and 10 = complete interference with sleep,
unable to sleep because of pain) for evaluating the qual-
ity of sleep in the same way that the PI-NRS evaluates
pain levels. The symptoms of PDN are worse at night,
and patients with PDN have more impairment in their
sleep measurements. Sleep impairments are a major
cause of the decreased quality of life of patients with
PDN. [18]. It is important to measure sleep disturbance
to identify the effect of the treatment on the PDN.
The SF-36 will be used for assessing the HRQoL of the
PDN at the 5th, 9th and 17th week from the baseline. It
is composed of 36 questions in eight domains: physical
functioning, role-physical, bodily pain, general health, vi-
tality, social functioning, role-emotional and mental
health [39]. It can be completed in 5 to 10 minutes, and
higher scores indicate a better HRQoL. The SF-36 is
used to measure the functional health and well-being of
patients and non-patients. There is a Korean version of
the SF-36, and Han et al. confirmed its reliability and
validity for use in the HRQoL of life measurements with
elderly Korean patients [40].To assess depression, BDI scores will be used at the
5th, 9th and 17th weeks from baseline. The BDI, devel-
oped by AT Beck in 1967, is one of the most widely used
self-rating scales for measuring the severity of depres-
sion. It consists of a 21-question multiple-choice ques-
tionnaire to assess depression symptoms of hopelessness
and irritability, cognition (for example, guilt and feelings
of being punished) and physical symptoms (for example,
fatigue and weight loss). Higher total scores indicate a
more severe level of depression.
The patient global assessment will be measured by
PGIC, a self-reported seven-point categorical scale that
is used to evaluate the overall improvement after treat-
ment [34]. Participants subjectively evaluate themselves
as to the improvement of their symptoms at 5th, 9th
and 17th weeks from baseline by selecting one of the
following seven stages: 1) very much improved, 2) much
improved, 3) minimally improved, 4) no change, 5) mini-
mally worse, 6) much worse or 7) very much worse.
The Credibility and Expectancy Questionnaire [41]
with a nine-point Likert scale will be used to evaluate
the treatment expectancy of the participants. At the
first visit, the participants will select the scores (1 =
not at all, 5 = somewhat and 9 = very much) for the
following question, “How much do you feel that the
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symptoms?”
Sample size
There were no previous clinical trials to evaluate the ef-
fect of electroacupuncture for treating PDN with a
three-armed RCT. A formal power calculation was not
performed because this study is planned to evaluate its
feasibility and to calculate a required sample size for
subsequent definitive randomized clinical trials. A sam-
ple size of 15 per group and a total number of 45 will be
included; considering a possible 20% drop out rate, this
number of subjects is the recommended minimum num-
ber per group to be considered for pilot studies [42].
Statistical analysis
The study has one primary null hypothesis: there is no
difference in the change of the primary endpoint among
the three groups after eight weeks of treatment. The
intention-to-treat (ITT) analysis as a primary analysis
will be performed, including all participants who are
randomized and have provided baseline data, and the
per-protocol (PP) analysis will be conducted as a re-
ference, including the participants who complete the
study following the predefined protocol. The minimum
number of treatments for the PP set is more than 12 ses-
sions without three continuous absences from the treat-
ment sessions. The mixed model for repeated measures
(MMRM) will be used to handle missing data. The data
will be presented as the mean (standard deviations or
95% confidence intervals) or median (quartiles) for con-
tinuous data (for example, age and duration of disease)
and n (%) for categorical data (for example, gender and
whether taking a pain control medication).
For the descriptive analysis, we will perform a two-
sample t-test or a Wilcoxon rank sum test for continu-
ous data and a chi-squared test or Fisher’s exact test for
categorical data, according to whether the data are nor-
mally distributed or skewed.
For the confirmatory analysis, an analysis of covariance
(ANCOVA) with the baseline measurements as a covari-
ate, the treatment group as a fixed effect, and taking a
pain control medication as a stratified variable will be
used for the primary outcome (PI-NRS) and secondary
outcomes (SF-MPQ, sleep disturbance score, SF-36 and
BDI) at the 5th, 9th and 17th weeks from baseline (after
randomization). The PGIC and blinding test will be ana-
lyzed using a chi-squared test. If a significant difference
is identified among the three groups, then multiple com-
parisons will be conducted to determine which groups
are different. ANCOVA without considering stratifica-
tion will be performed to compare the covariance with
the main analysis to determine whether taking a pain
control medication is a suitable factor that affects thetreatment outcome. The mean change in the values fol-
lowing the treatment in each group will be examined
using a paired t-test or a Wilcoxon signed rank test, and
95% confidence intervals will be presented. To identify a
trend, a repeated measures analysis of variance will be
performed for differences over time and among groups.
All of the analyses will be performed using a significance
level of 5% by SAS statistical software (Version 9.1.3;
SAS institute Inc., Cary, NC, USA).
Data and safety monitoring
Regular monitoring will be conducted to ensure quality
control of the data according to the planned protocol
and SOPs. Monitors who are blinded to the allocation
information will evaluate whether the recruitment pro-
cedures are correctly performed and whether the data
are adequately recorded according to the protocol in the
case report forms. If there are necessary changes in the
study methods, such as changes to the eligibility criteria,
treatment regimens or duration of follow-up, then the
investigators would discuss these issues with independ-
ent researchers and statisticians. In the event that severe
adverse events and crucial issues occur, the investigators
will determine whether these issues are acceptable or if
it will be necessary to amend or end the trial.
Adverse events
Practitioners will record all unexpected and unintended
responses that are not necessarily related to electro-
acupuncture treatment as reported by each participant
on an adverse event report form at every visit. The ad-
verse events known to be related to electroacupuncture
treatment are pain, dizziness, bleeding, aggravation, diz-
ziness, pain, anxiety and infection [22]. A causal rela-
tionship between the electroacupuncture treatment and
adverse events will be evaluated using a six-grade scale
(1 = definitely related, 2 = probably related, 3 = possibly
related, 4 = probably not related, 5 = definitely not related
and 6 = unknown), and the seriousness of the adverse
events will be scored using a four-point scale (1 = mild,
2 = moderate, 3 = severe and 4 = extremely severe) by the
assessment of two researchers (SL, SYJ).
Participant protections and ethics
The study was planned in accordance with the Helsinki
Declaration and the Korean Good Clinical Practice
Guidelines to protect the participants and was approved
by the institutional review board (IRB) of Daejeon Uni-
versity Hospital (djomc-83). Informing the participants
about the potential benefits, risks, alternatives and res-
ponsibilities during the study is performed by the resear-
chers through the consent process. To avoid potential
adverse events, if the practitioner judges that the partici-
pant is not suitable for electroacupuncture treatment due
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or a common cold, then the treatment will be rescheduled
within three days.
Discussion
The object of this study is to assess the effectiveness and
safety of electroacupuncture for treating PDN. We
designed a three-armed parallel study to determine the
specific effect of electroacupuncture (the electroacu-
puncture group versus the sham group) and the overall
effect of electroacupuncture (the electroacupuncture
group versus the usual care group). Because medical de-
vices tend to have more enhanced non-specific effects
than do placebo pills [43,44] and it is difficult to separate
some needling components (for example, stimulation of
the skin) of acupuncture treatment from sham acupunc-
ture [29], it is necessary to investigate the specific and
non-specific effects of acupuncture by including a sham
control and the usual care which is applied to the other
groups [45].
Conventional usual care includes lifestyle intervention
as well as routine antihyperglycemic medications. The
Diabetes Prevention Program provides healthy diet and
exercise counseling to type 2 DM patients as an inten-
sive lifestyle intervention [46]. One large trial assessing
the long-term effects of lifestyle intervention in type 2
diabetes patients emphasized a low-calorie, moderate-fat
diet and increased physical activity to reduce cardiovas-
cular disease risk [13]. Another translational trial showed
that lifestyle interventions for pre-diabetic neuropathy
resulted in partial cutaneous reinnervation and de-
creased pain [47]. Therefore, education and counseling
for diet and exercise are included in our trial as part of
usual care.
It is known that electroacupuncture and manual acu-
puncture operate through different scientific mecha-
nisms [22,48]. A study in rats suggested that manual
acupuncture analgesia probably occurred through a
contribution from collagen fibers, whereas electroa-
cupuncture analgesia is involved with peripheral nerve
receptors [49]. Some studies have suggested that elec-
troacupuncture is more effective than is manual acu-
puncture in raising the pain threshold and changing the
blood flow by causing a greater effect on central endor-
phins, such as beta-endorphin or dynophins [50-52].
Other studies have reported that manual acupuncture
and electroacupuncture have comparable effects [53,54],
or that manual acupuncture is superior to electroacu-
puncture in similar conditions because it more readily
elicits deqi sensations, which are conveyed by type III
and IV nerve fibers [48].
In diabetic neuropathy, some studies in animal models
have shown that electroacupuncture is effective in con-
trolling neuropathic pain and functional deficits [55,56].One RCT suggested that electroacupuncture is more
effective in improving physical activity and QoL and
reduces the need for oral analgesic medication than
manual acupuncture [31]. Electrical stimulation, such
as percutaneous nerve stimulation, was recommended
as level B in recent clinical guidelines [3]. Considering
these previous examinations and the clinical experience of
our DKMs, we decided to use electroacupuncture for this
clinical trial.
Frequency is known to be a key electroacupuncture
parameter, and the effects of electroacupuncture are
different according to the frequency. It is generally re-
cognized that low frequency stimulation (LF) < 10Hz
releases opioid peptides, such as beta-endorphin and
enkephalin, and has a relatively longer-lasting and gener-
alized effect, while high frequency stimulation (HF)
around 80 to 200 Hz releases different opioid peptides,
such as dynorphin, and has a relatively short-term and
predominantly segmental effect [48]. In practice, it is
recommend that both LF and HF be used together as a
dense-disperse (DD) wave because the DD mode can
prevent nerve accommodation and release various neu-
rotransmitters [22,48]. We planned to apply 2/120 Hz
mixed frequencies in the electroacupuncture group.
Most medications for PDN offer only temporary relief
from neuropathic pain. However, some etiology-based
treatments such as alpha-lipoic acid were reported to
improve reduced nerve conduction velocity as well as
subjective outcomes [57]. Recently, a randomized sham-
controlled trial for PDN showed that acupuncture was
more effective than sham acupuncture in both improv-
ing nerve conduction velocity and reducing pain [33].
The results indicate that for PDN, acupuncture is supe-
rior to placebo control; however, the mechanisms in-
volved in the effects of acupuncture on nerve recovery
and microvascular changes in diabetic neuropathy are
unknown.
In spite of the large number of studies of acupuncture
for PDN, the quality of the reports was limited, and their
clinical value cannot be determined [25]. To reduce the
risk of bias, we will conduct our study with proper
randomization and allocation concealment. In addition,
we will use appropriate blinding for the assessors, partic-
ipants (in the electroacupuncture and sham group), data
manager, statisticians and study monitors (of all groups).
This trial will be the first well-designed placebo-
controlled RCT to assess the effectiveness and safety of
electroacupuncture for treating PDN and to provide the
basis for a future large-scale, multicenter trial.
Trial status
Recruitment for the trial began in June 2012 and will be
completed by the end of July 2013. We expect that the
results will be reported by the end of 2014.
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